- Home
- CRAC vs KZIA Comparison
CRAC vs KZIA Comparison
Compare CRAC & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
SELL
Current Price
$8.16
Company Overview
Basic Information| Metric | CRAC | KZIA |
|---|---|---|
| Founded | 2025 | 1994 |
| Country | Cayman Islands | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.7M | 186.7M |
| IPO Year | 2025 | 2002 |
Fundamental Metrics
Financial Performance| Metric | CRAC | KZIA |
|---|---|---|
| Price | $10.28 | $8.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $29.33 |
| AVG Volume (30 Days) | 43.0K | ★ 200.2K |
| Earning Date | 01-01-0001 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $4.86 |
| 52 Week High | $10.30 | $17.40 |
Technical Indicators
Market Signals| Indicator | CRAC | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 65.06 | 42.26 |
| Support Level | $10.18 | $6.72 |
| Resistance Level | N/A | $14.85 |
| Average True Range (ATR) | 0.01 | 0.63 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 60.00 | 55.65 |
Price Performance
Historical Comparison CRAC
KZIA
About CRAC Crown Reserve Acquisition Corp. I Class A Ordinary Shares
Crown Reserve Acquisition Corp I is a blank check company.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.